Advanced non-small-cell lung cancer: adjunctive interferon γ in induction and maintenance therapy

C, Prior; Oroszy, S; Oberaigner, Wilhelm; Ambrosch, Gerhard; Mohn-Staudner, Andrea; Pfeifer, W.; Pirker, Robert; Huber, H.

doi:10.1007/s004320050240

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Over the last 5 years, there have been a large number of trials involving maintenance in patients with advanced NSCLC including evaluation of cytotoxic (e.g., paclitaxel, docetaxel, and gemcitabine [Gem]) and noncytotoxic agents (e.g., erlotinib [Erl] and bevacizumab [Bev]). [7][8][9][10][11][12][13][14][15][16] The majority of these trials lacked a placebo control arm, and most were not adequately powered to detect a significant survival benefit for maintenance therapy.…”

mentioning

confidence: 99%

Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

Klein

Wielage

Muehlenbein

et al. 2010

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Compared with observation and other agents used and/or reimbursed for maintenance therapy in advanced NSCLC, Pem may be considered cost-effective, particularly in patients with nonsquamous cell histology. This analysis is the first to evaluate the cost-effectiveness of maintenance therapy in advanced NSCLC and emphasizes the importance of histology in identifying the appropriate patient for Pem maintenance therapy.

show abstract

mentioning

confidence: 99%

Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

Klein

Wielage

Muehlenbein

et al. 2010

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…In addition, for patients with advanced NSCLC, an adjunctive dose of 100 µg IFN-γ, given three times weekly in the induction and maintenance phase, is feasible. Survival data seem favorable; thus, this regimen may warrant further investigation in a phase III study (Prior et al, 1999). However, the mechanisms of action of IFN-γ in NSCLC are merely speculative.…”

Section: Introductionmentioning

confidence: 99%

Induction of Indoleamine 2,3-dioxygenase (IDO) Enzymatic Activity Contributes to Interferon-Gamma Induced Apoptosis and Death Receptor 5 Expression in Human Non-small Cell Lung Cancer Cells

Chung

Tan

Chan

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Maintenance with interferon-␣2a [58], interferon-␥ [59], bexarotene [60], uracil-tegafur [8], or BLP25 liposome vaccine [61] seems feasible, but it is unclear whether these agents are really effective. New molecular targeted agents (i.e., inhibitors of the epidermal growth factor receptor tyrosine kinase) are worth evaluation as maintenance treatment.…”

Section: Consolidation/maintenance Chemotherapymentioning

confidence: 99%

Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature

Grossi¹,

Aita

Follador

et al. 2007

The Oncologist

View full text Add to dashboard Cite

LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Describe the new chemotherapy design strategies (i.e., sequential, alternating, and maintenance/consolidation chemotherapy).2. Identify potential advantages and drawbacks of these new strategies in advanced NSCLC.3. Discuss the results of clinical trials testing sequential, alternating, and maintenance/consolidation chemotherapy in advanced NSCLC.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTA platinum-based doublet with a third-generation agent (paclitaxel, vinorelbine, gemcitabine, docetaxel) represents the standard first-line treatment for advanced nonsmall cell lung cancer patients with good performance status (PS). Traditional chemotherapy provides response rates of 20%-40% and a median survival of 8 -10 months.In an attempt to improve its outcome, alternative schedules have been proposed, namely sequential, alternating, and maintenance/consolidation therapy. Sequential chemotherapy with a platinum-based doublet followed by a single agent is feasible in patients with good PS; preliminary results from randomized phase III trials with combination chemotherapy as a comparator are promising, suggesting similar efficacy and a better toxicity profile for the sequential arm. The use of sequential single agents is an option for elderly and frail patients unsuitable for a platinum-based combination.Based on trials published so far, it is unlikely that an alternating chemotherapy strategy will be proven superior to standard chemotherapy in patients with good PS. However, sufficient evidence exists that it could be appropriate in the elderly or in unfit individuals.Consolidation/maintenance chemotherapy may provide additional benefit for patients achieving disease control after standard first-line chemotherapy. Better results are seen when maintenance consists of an agent that has proven active in the induction phase. Further evaluation of this strategy, as well as of consolidation/maintenance therapy with targeted agents, is warranted.In conclusion, these approaches may improve the out-

show abstract

Advanced non-small-cell lung cancer: adjunctive interferon γ in induction and maintenance therapy

Abstract: In patients with advanced NSCLC, an adjunctive dose of 100 microg IFNgamma, given three times weekly in the induction and maintenance phase, is feasible. Survival data seem favourable so this regimen may warrant further investigation in a phase III study.

Cited by 7 publications

References 24 publications

Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

Induction of Indoleamine 2,3-dioxygenase (IDO) Enzymatic Activity Contributes to Interferon-Gamma Induced Apoptosis and Death Receptor 5 Expression in Human Non-small Cell Lung Cancer Cells

Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature

Contact Info

Product

Resources

About